Demaria, O. et al. Harnessing innate immunity in most cancers remedy. Nature 574, 45–56 (2019).
Vonderheide, R. H. CD47 blockade as one other immune checkpoint remedy for most cancers. Nat. Med. 21, 1122–1123 (2015).
Weiskopf, Ok. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).
Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRPα immune checkpoint. Immunity 52, 742–752 (2020).
Jalil, A. R., Andrechak, J. C. & Discher, D. E. Macrophage checkpoint blockade: outcomes from preliminary medical trials, binding analyses, and CD47-SIRPα construction–perform. Antib. Ther. 3, 80–94 (2020).
Zhang, W. et al. Advances in anti-tumor remedies concentrating on the CD47/SIRPα axis. Entrance. Immunol. 11, 18 (2020).
Sikic, B. I. et al. First-in-human, first-in-class section I trial of the anti-CD47 antibody Hu5F9-G4 in sufferers with superior cancers. J. Clin. Oncol. 37, 946–953 (2019).
Ansell, S. M. et al. Section I examine of the CD47 blocker TTI-621 in sufferers with relapsed or refractory hematologic malignancies. Clin. Most cancers Res. 27, 2190–2199 (2021).
Eladl, E. et al. Function of CD47 in hematological malignancies. J. Hematol. Oncol. 13, 96 (2020).
Chen, J. et al. SLAMF7 is crucial for phagocytosis of haematopoietic tumour cells through Mac-1 integrin. Nature 544, 493–497 (2017).
Feng, M. et al. Phagocytosis checkpoints as new targets for most cancers immunotherapy. Nat. Rev. Most cancers 19, 568–586 (2019).
Uger, R. & Johnson, L. Blockade of the CD47-SIRPα axis: a promising method for most cancers immunotherapy. Professional Opin. Biol. Ther. 20, 5–8 (2020).
Zhong, C. et al. Poly(I:C) enhances the efficacy of phagocytosis checkpoint blockade immunotherapy by inducing IL-6 manufacturing. J. Leukoc. Biol. 110, 1197–1208 (2021).
Cao, X. et al. Impact of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast most cancers. J. Immunother. Most cancers 9, e002022 (2021).
Zhang, A. L. et al. Twin concentrating on of CTLA-4 and CD47 on T-reg cells promotes immunity in opposition to stable tumors. Sci. Transl. Med. 13, eabg8693 (2021).
Shi, Y. & Lammers, T. Combining nanomedicine and immunotherapy. Acc. Chem. Res. 52, 1543–1554 (2019).
Yuan, H. et al. Multivalent bi-specific nanobioconjugate engager for focused most cancers immunotherapy. Nat. Nanotechnol. 12, 763–769 (2017).
Weissleder, R., Kelly, Ok., Solar, E. Y., Shtatland, T. & Josephson, L. Cell-specific concentrating on of nanoparticles by multivalent attachment of small molecules. Nat. Biotechnol. 23, 1418–1423 (2005).
Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499 (2017).
Pazina, T. et al. Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of a number of myeloma. Most cancers Immunol. Res. 7, 1633–1646 (2019).
Lu, Ok. et al. Low-dose X-ray radiotherapy–radiodynamic remedy through nanoscale metallic–natural frameworks enhances checkpoint blockade immunotherapy. Nat. Biomed. Eng. 2, 600–610 (2018).
Shae, D. et al. Endosomolytic polymersomes improve the exercise of cyclic dinucleotide STING agonists to boost most cancers immunotherapy. Nat. Nanotechnol. 14, 269–278 (2019).
Li, X. et al. Most cancers immunotherapy based mostly on image-guided STING activation by nucleotide nanocomplex-decorated ultrasound microbubbles. Nat. Nanotechnol. 7, 891–899 (2022).
Liao, W., Lin, J. X. & Leonard, W. J. Interleukin-2 on the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38, 13–25 (2013).
Morad, G., Helmink, B. A., Sharma, P. & Wargo, J. A. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 184, 5309–5337 (2021).
Alizadeh, D. et al. IFNγ is crucial for CAR T cell-mediated myeloid activation and induction of endogenous immunity. Most cancers Discov. 11, 2248–2265 (2021).
Pitter, M. R. & Zou, W. Uncovering the immunoregulatory perform and therapeutic potential of the PD-1/PD-L1 axis in most cancers. Most cancers Res. 81, 5141–5143 (2021).
Jiang, X. et al. Function of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape. Mol. Most cancers 18, 10 (2019).
Su, S. et al. Immune checkpoint inhibition overcomes ADCP-induced immunosuppression by macrophages.Cell 175, 442–457.e23 (2018).
von Roemeling, C. A. et al. Therapeutic modulation of phagocytosis in glioblastoma can activate each innate and adaptive antitumour immunity. Nat. Commun. 11, 1508 (2020).
Kosaka, A. et al. CD47 blockade enhances the efficacy of intratumoral STING-targeting remedy by activating phagocytes. J. Exp. Med. 218, e20200792 (2021).
Hopfner, Ok. P. & Hornung, V. Molecular mechanisms and mobile features of cGAS–STING signalling. Nat. Rev. Mol. Cell Biol. 21, 501–521 (2020).
Martin, G. R., Blomquist, C. M., Henare, Ok. L. & Jirik, F. R. Stimulator of interferon genes (STING) activation exacerbates experimental colitis in mice. Sci. Rep. 9, 14281 (2019).
Abdullah, A. et al. STING-mediated type-I interferons contribute to the neuroinflammatory course of and detrimental results following traumatic mind damage. J. Neuroinflammation 15, 323 (2018).
Mathur, V. et al. Activation of the STING-dependent sort I interferon response reduces microglial reactivity and neuroinflammation. Neuron 96, 1290–1302.e6 (2017).
Li, Z. et al. Immunogenic cell dying prompts the tumor immune microenvironment to spice up the immunotherapy effectivity. Adv. Sci. (Weinh.) 9, e2201734 (2022).
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Sort I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).
Salvagno, C. et al. Therapeutic concentrating on of macrophages enhances chemotherapy efficacy by unleashing sort I interferon response. Nat. Cell Biol. 21, 511–521 (2019).
Zhang, Z. et al. Folate receptor α related to triple-negative breast most cancers and poor prognosis. Arch. Pathol. Lab. Med. 138, 890–895 (2014).
Tune, D. G. et al. Efficient adoptive immunotherapy of triple-negative breast most cancers by folate receptor-alpha redirected CAR T cells is influenced by floor antigen expression degree. J. Hematol. Oncol. 9, 56 (2016).
Aldea, M. et al. Overcoming resistance to tumor-targeted and immune-targeted therapies. Most cancers Discov. 11, 874–899 (2021).
Han, C. et al. Tumor cells suppress radiation-induced immunity by hijacking caspase 9 signaling. Nat. Immunol. 21, 546–554 (2020).
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
Liao, J. B. et al. Preservation of tumor–host immune interactions with luciferase-tagged imaging in a murine mannequin of ovarian most cancers. J. Immunother. Most cancers 3, 16 (2015).
Qie, Y. et al. Floor modification of nanoparticles allows selective evasion of phagocytic clearance by distinct macrophage phenotypes. Sci. Rep. 6, 26269 (2016).
Mosser, D. M. & Zhang, X. Activation of murine macrophages. Curr. Protoc. Immunol. 83, 14.2.1–14.2.8 (2008).
Weiskopf, Ok. et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science 341, 88–91 (2013).
Schmittgen, T. D. & Livak, Ok. J. Analyzing real-time PCR information by the comparative CT methodology. Nat. Protoc. 3, 1101–1108 (2008).
Evans, B. C. et al. Ex vivo purple blood cell hemolysis assay for the analysis of pH-responsive endosomolytic brokers for cytosolic supply of biomacromolecular medication. J. Vis. Exp. 73, 50166 (2013).
